Relay Therapeutics, Inc. (RLAY)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
16.28 USD
-1.02
(-5.896%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 16.27 -0.01 (-0.010%) ⇩ (Oct. 16, 2026, 4:19 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:48 a.m. EDT
The long-term investment case is effectively broken. The company has endured five consecutive years of negative annual returns, culminating in an 84.58% cumulative decline over the last half-decade. This is not a temporary setback; it is a structural deterioration where the market has repeatedly rejected the business thesis. Fundamentals confirm the distress: revenue has contracted by nearly 50%, operating margins are deeply negative, and the company is burning cash with no path to profitability visible in the forward estimates. While the balance sheet currently holds due to a recent capital raise, the underlying asset quality has eroded significantly. In the short term, the stock is trapped in a tug-of-war between a recent 74% rally and the weight of its history. The recent price action shows a pullback from highs, trading below its 50-day average, which suggests the initial euphoria is fading. Options activity reveals a disconnect: traders are buying cheap insurance against a crash (deep puts) while placing long-term lottery tickets on a miracle recovery (far-dated calls). This creates a volatile, choppy environment unsuitable for a standard entry. The statistical forecast offers no guidance, confirming the noise-heavy nature of the price action. Until the company demonstrates sustained revenue growth and a return to profitability, the risk of permanent capital loss outweighs any potential for a rebound. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.064192 |
| AutoETS | 0.069999 |
| AutoTheta | 0.112332 |
| AutoARIMA | 0.193520 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 6.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.941 |
| Excess Kurtosis | -0.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.445 |
| Revenue per Share | 0.057 |
| Market Cap | 3,567,625,984 |
| Forward P/E | -9.97 |
| Beta | 1.73 |
| Website | https://www.relaytx.com |
As of Oct. 10, 2026, 7:48 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional move. There is heavy put volume at deep strikes (below $10) and moderate out-of-the-money put walls, indicating a fear of further downside or a 'crash' scenario. Conversely, there is massive open interest in far-dated calls ($30 strike in 2028), suggesting a speculative bet on a massive recovery or biotech breakthrough, while near-term call activity is thin and dominated by out-of-the-money strikes. The implied volatility skew shows elevated premiums for deep puts, reflecting a high-risk sentiment profile.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.6656394 |
| Address1 | 60 Hampshire Street |
| All Time High | 64.37 |
| All Time Low | 1.775 |
| Ask | 24.83 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 2,796,770 |
| Average Daily Volume3 Month | 2,770,987 |
| Average Volume | 2,770,987 |
| Average Volume10Days | 2,796,770 |
| Beta | 1.731 |
| Bid | 14.35 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 4.073 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.28 |
| Current Ratio | 18.268 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 17.17 |
| Day Low | 16.13 |
| Debt To Equity | 3.445 |
| Display Name | Relay Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -308,224,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -9.444 |
| Enterprise To Revenue | 281.244 |
| Enterprise Value | 2,910,874,112 |
| Eps Current Year | -1.61364 |
| Eps Forward | -1.63227 |
| Eps Trailing Twelve Months | -1.56 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 18.914 |
| Fifty Day Average Change | -2.6339989 |
| Fifty Day Average Change Percent | -0.13926187 |
| Fifty Two Week Change Percent | 166.56393 |
| Fifty Two Week High | 21.27 |
| Fifty Two Week High Change | -4.99 |
| Fifty Two Week High Change Percent | -0.2346027 |
| Fifty Two Week Low | 5.95 |
| Fifty Two Week Low Change | 10.330001 |
| Fifty Two Week Low Change Percent | 1.7361346 |
| Fifty Two Week Range | 5.95 - 21.27 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,594,906,200,000 |
| Float Shares | 145,549,488 |
| Forward Eps | -1.63227 |
| Forward P E | -9.973841 |
| Free Cashflow | -119,241,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 202 |
| Fullday Change | -1.0299988 |
| Fullday Change Percent | -5.9537506 |
| Fullday Price | 16.27 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -258,496,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.015759999 |
| Held Percent Institutions | 1.10878 |
| Implied Shares Outstanding | 219,141,631 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-07-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Relay Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 3,567,625,984 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_384027698 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -286,036,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,951,123,606 |
| Number Of Analyst Opinions | 12 |
| Open | 17.17 |
| Operating Cashflow | -212,204,992 |
| Operating Margins | -259.49716 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 370 8837 |
| Post Market Change | -0.010000229 |
| Post Market Change Percent | -0.061426464 |
| Post Market Price | 16.27 |
| Post Market Time | 1,792,181,947 |
| Previous Close | 17.3 |
| Price Eps Current Year | -10.088992 |
| Price Hint | 2 |
| Price To Book | 3.997054 |
| Price To Sales Trailing12 Months | 344.69815 |
| Profit Margins | 0.0 |
| Quick Ratio | 17.93 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.23077 |
| Region | US |
| Regular Market Change | -1.0199986 |
| Regular Market Change Percent | -5.895946 |
| Regular Market Day High | 17.17 |
| Regular Market Day Low | 16.13 |
| Regular Market Day Range | 16.13 - 17.17 |
| Regular Market Open | 17.17 |
| Regular Market Previous Close | 17.3 |
| Regular Market Price | 16.28 |
| Regular Market Time | 1,792,180,800 |
| Regular Market Volume | 2,366,617 |
| Return On Assets | -0.22875999 |
| Return On Equity | -0.36773998 |
| Revenue Growth | -0.483 |
| Revenue Per Share | 0.057 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 219,141,631 |
| Shares Percent Shares Out | 0.2133 |
| Shares Short | 46,746,942 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 43,550,416 |
| Short Name | Relay Therapeutics, Inc. |
| Short Percent Of Float | 0.2484 |
| Short Ratio | 13.32 |
| Source Interval | 15 |
| State | MA |
| Symbol | RLAY |
| Target High Price | 32.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 27.58333 |
| Target Median Price | 27.5 |
| Total Cash | 910,934,016 |
| Total Cash Per Share | 4.157 |
| Total Debt | 30,658,000 |
| Total Revenue | 10,350,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.435925 |
| Two Hundred Day Average Change | 1.8440762 |
| Two Hundred Day Average Change Percent | 0.12774216 |
| Type Disp | Equity |
| Volume | 2,366,617 |
| Website | https://www.relaytx.com |
| Zip | 2,139 |